Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate

2/14/24 4:16:43 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AYTU alert in real time by email

Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million which beat the analyst consensus estimate of $21.75 million by 5.47 percent. This is a 12.73 percent decrease over sales of $26.28 million the same period last year.

Get the next $AYTU alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AYTU

Date	Price Target	Rating	Analyst

More analyst ratings

$AYTU
Press Releases

Fastest customizable press release news feed in the world

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year."We are honored to be recognized for the fourth consecutive year as a member of the Deloitte Technology Fast 500 list of the most rapidly growing companies," commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "During fiscal 2024, we continued to successfully reposition
11/22/24 9:00:00 AM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flowRyan Selhorn promoted to Chief Financial OfficerCompany to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / November 13, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today ann
11/13/24 4:05:00 PM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, November 13, 2024, at 4:30 p.m. Eastern timeCall-in Information: Interested parties can access the conference call by dialing (877) 545-
11/6/24 5:20:00 PM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care

$AYTU
Financials

Live finance-specific insights

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flowRyan Selhorn promoted to Chief Financial OfficerCompany to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / November 13, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today ann
11/13/24 4:05:00 PM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, November 13, 2024, at 4:30 p.m. Eastern timeCall-in Information: Interested parties can access the conference call by dialing (877) 545-
11/6/24 5:20:00 PM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 millionFull year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023$20.0 million cash balance at June 30, 2024Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levelsCompany to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / September 26, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel ther
9/26/24 4:15:00 PM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care

$AYTU
Market Insights

Live Market Insights

Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 73.06 percent increase over losses of $(1.93) per share from the same period last year. The company reported quarterly sales of $17.993 million which beat the analyst consensus estimate of $17.346 million by 3.73 percent. This is a 20.85 percent decrease over sales of $22.733 million the same period last year.
5/15/24 4:27:32 PM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care
Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million which beat the analyst consensus estimate of $21.75 million by 5.47 percent. This is a 12.73 percent decrease over sales of $26.28 million the same period last year.
2/14/24 4:16:43 PM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care
Earnings Scheduled For February 14, 2024
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. • CAE (NYSE:CAE) is estimated to report quarterly earnings at $0.18 per share on revenue of $819.57 million. • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.42 per share on revenue of $6.66 billion. • Great Lakes Dredge & Dock (NASDAQ:GLDD) is estimated to report quarterly earnings at $0.10 per share on revenue of $183.47 million. • Louisiana-Pacific (NYSE:LPX) is likely to report quarterly earnings at $0.55 per share on revenue of $619.97 million. • Martin Marietta Materials (NYSE:MLM) is projected to repor
2/14/24 4:48:44 AM ET
$ACGL
$ADPT
$AEMD
$ALB
Property-Casualty Insurers
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to [email protected]'s presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this LINK or visit the Company's website.If attendees are not able to
11/30/23 8:00:00 AM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki will serve as a member of Aytu's executive committee and will report to Josh Disbrow, chief executive officer. Mr. Oki will provide leadership and oversight of the company's financial operations and planning, accounting, information technology and select other functions."On behalf of the entire company, I am delighted to welcome Mark to Aytu and look forward to partnering with him as we
1/4/22 8:00:00 AM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline -- Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year -- Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET -ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commerciali
5/17/21 4:01:00 PM ET
$AYTU
Biotechnology: Pharmaceutical Preparations
Health Care

Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate

Chat with this insight

Recent Analyst Ratings for
$AYTU

$AYTU
Press Releases

Fastest customizable press release news feed in the world

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

$AYTU
Financials

Live finance-specific insights

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

$AYTU
SEC Filings

SEC Form 10-Q filed by Aytu BioPharma Inc.

Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form EFFECT filed by Aytu BioPharma Inc.

$AYTU
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Selhorn Ryan J was granted 14,000 shares, increasing direct ownership by 739% to 15,895 units (SEC Form 4)

New insider Selhorn Ryan J claimed ownership of 1,895 shares (SEC Form 3)

Director Dockery Carl was granted 1,500 shares, increasing direct ownership by 17% to 10,440 units (SEC Form 4)

$AYTU
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$AYTU
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Cantor Fitzgerald initiated coverage on Aytu BioPharma with a new price target

Amendment: SEC Form SC 13G/A filed by Aytu BioPharma Inc.

Amendment: SEC Form SC 13D/A filed by Aytu BioPharma Inc.

SEC Form SC 13G/A filed by Aytu BioPharma Inc. (Amendment)

$AYTU
Market Insights

Live Market Insights

Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate

Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate

Earnings Scheduled For February 14, 2024

$AYTU
Leadership Updates

Live Leadership Updates

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Aytu BioPharma Appoints Mark Oki as Chief Financial Officer

Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate

Chat with this insight

Recent Analyst Ratings for $AYTU

$AYTU Press Releases

Fastest customizable press release news feed in the world

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

$AYTU Financials

Live finance-specific insights

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

$AYTU SEC Filings

SEC Form 10-Q filed by Aytu BioPharma Inc.

Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form EFFECT filed by Aytu BioPharma Inc.

$AYTU Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Selhorn Ryan J was granted 14,000 shares, increasing direct ownership by 739% to 15,895 units (SEC Form 4)

New insider Selhorn Ryan J claimed ownership of 1,895 shares (SEC Form 3)

Director Dockery Carl was granted 1,500 shares, increasing direct ownership by 17% to 10,440 units (SEC Form 4)

$AYTU Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$AYTU Large Ownership Changes

This live feed shows all institutional transactions in real time.

Cantor Fitzgerald initiated coverage on Aytu BioPharma with a new price target

Amendment: SEC Form SC 13G/A filed by Aytu BioPharma Inc.

Amendment: SEC Form SC 13D/A filed by Aytu BioPharma Inc.

SEC Form SC 13G/A filed by Aytu BioPharma Inc. (Amendment)

$AYTU Market Insights

Live Market Insights

Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate

Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate

Earnings Scheduled For February 14, 2024

$AYTU Leadership Updates

Live Leadership Updates

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Aytu BioPharma Appoints Mark Oki as Chief Financial Officer

Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

Recent Analyst Ratings for
$AYTU

$AYTU
Press Releases

$AYTU
Financials

$AYTU
SEC Filings

$AYTU
Insider Trading

$AYTU
Analyst Ratings

$AYTU
Large Ownership Changes

$AYTU
Market Insights

$AYTU
Leadership Updates